Skip to main content
PDX-models1920
Whitepaper

Genetically engineered PDX models as patient avatars in preclinical evaluation of acute leukemias

Dr. Irmela Jeremias from Helmholtz Munich and her team are using gene silencing techniques to evaluate the relevance of specific tumor alterations in PDX models. The aim is to discover dependencies and drug targets in acute leukemias to improve patients’ treatment and prognosis outcomes. And they’ve done just that — read the whitepaper to learn more about the study.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Genetically engineered PDX models as patient avatars in preclinical evaluation of acute leukemias

Download Whitepaper